Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study

First-line treatment in postmenopausal women with estrogen- and/or progesterone-positive breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen cognitive function, depressive symptoms, sleep quality and performance in basic activities of daily life as primary...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Sánchez, Javier, Mafla-España, Mayra Alejandra, Torregrosa, María Dolores, Cauli, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712768/
https://www.ncbi.nlm.nih.gov/pubmed/36462308
http://dx.doi.org/10.1016/j.breast.2022.11.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712768/
https://www.ncbi.nlm.nih.gov/pubmed/36462308
http://dx.doi.org/10.1016/j.breast.2022.11.007

Ejemplares similares